A preliminary study of pamidronic acid downregulation of angiogenic factors IGF-1/PECAM-1 expression in circulating level in bone metastatic breast cancer patients.
OBJECTIVE
To evaluate the expressions of circulating angiogenic factors affected by pamidronic acid (PA) intravenous infusion in bone metastatic breast cancer patients and the impact on their prognosis.


METHODS
Peripheral blood of ten bone metastatic breast cancer patients was collected for serum insulin-like growth factor-1 (IGF-1) and platelet endothelial cell adhesion molecule-1 expression detection just before and 2 days after PA infusion.


RESULTS
Both IGF-1 and platelet endothelial cell adhesion molecule-1 concentrations decreased after PA treatment for 48 hours (P<0.05). Modification was defined as >20% decrease recorded 2 days after PA administration. The decrease of IGF-1 was more significant in breast cancer patients who had received previous hormonotherapy. Moreover, the progression-free survival of first-line chemotherapy treatment of IGF-1 modified patients was longer than that of IGF-1 unmodified patients (P=0.009).


CONCLUSIONS
PA treatment could suppress circulating serum IGF-1 and platelet endothelial cell adhesion molecule-1 concentrations; moreover, the prognosis of patients in IGF-1 unmodified group was relatively poor.
Department of Pharmacy, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Key Lab of Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China.
Zeng
Z
Wang
Zhejiang Key Lab of Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China; Department of Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
Lei
L
Lei
Department of Pharmacy, Integrated Chinese and Western Medicine Hospital of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.
Xin-Jun
XJ
Cai
Department of Pharmacy, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Key Lab of Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China.
Ling Ya
LY
Chen
Zhejiang Key Lab of Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China; Department of Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
Meiqin
M
Yuan
Department of Pharmacy, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Key Lab of Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China.
Guonong
G
Yang
Department of Pharmacy, Hangzhou, Zhejiang, People's Republic of China; Zhejiang Key Lab of Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China.
Ping
P
Huang
Zhejiang Key Lab of Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang, People's Republic of China; Department of Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
Xiaojia
X
Wang
bone metastatic breast cancer; insulin-like growth factor-1; pamidronic acid; platelet endothelial cell adhesion molecule-1; prognosis